The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
In the second edition of the Lantern Pharma Newsletter you will find:
1) Lantern has activated its first two Harmonic™ clinical trial sites:
2) The Harmonic™ clinical trial website is now live at www.harmonictrial.com.
3) A unique aspect of the Harmonic™ clinical trial is that liquid biopsies will be collected from patients and analyzed at 4 time points: at enrollment prior to treatment; after the initial 3 treatments; after 6 treatments; and at completion of treatment.
On September 22nd at 12:00pm ET, Lantern Pharma will be hosting a Key Opinion Leader (KOL) webinar on LP-184, LP-284, and the treatment of pediatric cancers.
The webinar will feature a leading pediatric cancer researcher and Lantern collaborator, Peter Houghton, Ph.D., Professor & Principal Investigator at Greehey Children's Cancer Research Institute (GCCRI) at UT Health Science Center-San Antonio.
Why it matters: September is Childhood Cancer Awareness Month and was created to drive awareness for pediatric cancer patients and the disparities that exist in pediatric cancer research and drug development:
Lantern entered a collaboration with Actuate Therapeutics, Inc. in Q2 of 2021 to leverage RADR® to accelerate the development of biomarkers for Actuate’s drug candidate, elraglusib (also known as 9-ING-41).
Why it matters: Using advanced ML ensemble based algorithms and other computational approaches, RADR® has aided in the identification of actionable biomarkers and modeling patient clinical response to elraglusib. These insights are being used to inform the design of Phase 2 randomized clinical trials for elraglusib.
What's next: These methods will be applied for biomarker validation and will be expanded to incorporate modeling with patient data including, RNA, ctDNA, and soluble biomarkers.
Lantern has received equity in Actuate and has the potential to receive additional equity upon meeting development milestones.
Lantern will be presenting new preclinical data at several conferences this quarter:
Additional information about the new preclinical data can be heard at the conference presentations or seen in upcoming press releases.
Lantern Pharma management will be presenting at:
H.C. Wainwright’s 24th Annual Global Investment Conference, September 12-14, 2022 in New York, NY. Click here to register.
MicroCap Rodeo Presents: Windy City Roundup, October 12-13, 2022 in Chicago, IL. Click here to register.
ThinkEquity Conference, October 26, 2022 in New York, NY. Click here to register.
In a recent RedChip Money Report interview, Panna discussed a wide range of topics including:
The full interview can be viewed here.
This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events, our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.